Financial Ratios Lumosa Therapeutics Co., Ltd.
Stocks
6535
TW0006535008
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.50 TWD | -1.39% |
|
-9.75% | -45.24% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -13.01 | -9.03 | -13.26 | -11.78 | -11.02 | |||||
Return on Total Capital | -14.42 | -10.05 | -15.08 | -13.22 | -12.04 | |||||
Return On Equity % | 5.18 | -26.63 | -16.16 | -26.03 | -20.11 | |||||
Return on Common Equity | 5.18 | -26.39 | -15.71 | -25.65 | -19.91 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 56.96 | 54.65 | 72.88 | 45.24 | 61.04 | |||||
SG&A Margin | 196.53 | 150.22 | 83.99 | 132.3 | 142.35 | |||||
EBITDA Margin % | -2.33T | -1.08T | -627.12 | -901.63 | -918.66 | |||||
EBITA Margin % | -2.33T | -1.09T | -631.42 | -912.09 | -930.73 | |||||
EBIT Margin % | -2.48T | -1.15T | -660.23 | -912.09 | -930.73 | |||||
Income From Continuing Operations Margin % | 552.62 | -1.89T | -439.83 | -1.12T | -967.37 | |||||
Net Income Margin % | 552.62 | -1.86T | -418.23 | -1.08T | -950.41 | |||||
Net Avail. For Common Margin % | 552.62 | -1.86T | -418.23 | -1.08T | -950.41 | |||||
Normalized Net Income Margin | -1.54T | -636.65 | -372.39 | -503.32 | -517.36 | |||||
Levered Free Cash Flow Margin | -1.69T | -777.49 | -372.63 | -459.75 | -723.54 | |||||
Unlevered Free Cash Flow Margin | -1.69T | -777.14 | -372.57 | -459.45 | -723.19 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | |||||
Fixed Assets Turnover | 1.07 | 2.58 | 3.23 | 1.66 | 2.1 | |||||
Receivables Turnover (Average Receivables) | 1.48 | 2.25 | 4.38 | 2.4 | 2.14 | |||||
Inventory Turnover (Average Inventory) | 0.13 | 0.13 | 0.15 | 0.21 | 0.14 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.23 | 6.44 | 4.75 | 7.64 | 7.37 | |||||
Quick Ratio | 6.6 | 5.65 | 3.98 | 6.92 | 6.28 | |||||
Operating Cash Flow to Current Liabilities | -2.02 | -1.4 | -1.49 | -1.47 | -2.75 | |||||
Days Sales Outstanding (Average Receivables) | 247.33 | 162.28 | 83.37 | 152.54 | 170.82 | |||||
Days Outstanding Inventory (Average Inventory) | 2.79T | 2.89T | 2.51T | 1.72T | 2.57T | |||||
Average Days Payable Outstanding | 45.65 | 73.67 | 471.58 | 34.86 | 33.37 | |||||
Cash Conversion Cycle (Average Days) | 2.99T | 2.97T | 2.13T | 1.84T | 2.71T | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.54 | 0.28 | 0.88 | 0.44 | 0.46 | |||||
Total Debt / Total Capital | 0.54 | 0.28 | 0.87 | 0.44 | 0.45 | |||||
LT Debt/Equity | 0.29 | 0.02 | 0.57 | 0.22 | - | |||||
Long-Term Debt / Total Capital | 0.29 | 0.02 | 0.56 | 0.22 | - | |||||
Total Liabilities / Total Assets | 9.8 | 11.44 | 13.75 | 9.63 | 7.94 | |||||
EBIT / Interest Expense | -1.65T | -2.05T | -8T | -1.91T | -1.66T | |||||
EBITDA / Interest Expense | -1.53T | -1.91T | -7.5T | -1.87T | -1.6T | |||||
(EBITDA - Capex) / Interest Expense | -1.53T | -1.92T | -7.81T | -1.87T | -1.61T | |||||
Total Debt / EBITDA | -0.03 | -0.02 | -0.04 | -0.02 | -0.02 | |||||
Net Debt / EBITDA | 3.62 | 4.15 | 2.36 | 3.85 | 2.46 | |||||
Total Debt / (EBITDA - Capex) | -0.03 | -0.02 | -0.03 | -0.02 | -0.02 | |||||
Net Debt / (EBITDA - Capex) | 3.62 | 4.12 | 2.27 | 3.85 | 2.45 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -19.81 | 53.45 | 113.63 | -31.21 | -8.49 | |||||
Gross Profit, 1 Yr. Growth % | -24.84 | 47.24 | 184.88 | -57.3 | 23.49 | |||||
EBITDA, 1 Yr. Growth % | 29.13 | -28.52 | 23.65 | -1.09 | -6.76 | |||||
EBITA, 1 Yr. Growth % | 28.07 | -28.47 | 24.13 | -0.63 | -6.62 | |||||
EBIT, 1 Yr. Growth % | 25.98 | -28.9 | 22.84 | -4.96 | -6.62 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -129.74 | -625.8 | -50.38 | 74.5 | -20.65 | |||||
Net Income, 1 Yr. Growth % | -129.74 | -615.56 | -51.88 | 78.45 | -19.83 | |||||
Normalized Net Income, 1 Yr. Growth % | 23.63 | -36.76 | 24.96 | -7.02 | -5.94 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -123.85 | -578.89 | -51.8 | 76.87 | -21.15 | |||||
Accounts Receivable, 1 Yr. Growth % | -29.96 | 44.43 | -14.25 | 71.91 | -37.46 | |||||
Inventory, 1 Yr. Growth % | 159.28 | 31.92 | -4.39 | -5.9 | 1.02 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -33.31 | -41.06 | 259.16 | -28.5 | -26.63 | |||||
Total Assets, 1 Yr. Growth % | 31.63 | -19.71 | -12.17 | 28.78 | -22.63 | |||||
Tangible Book Value, 1 Yr. Growth % | 47.01 | -22.75 | -12.65 | 36.5 | -21.04 | |||||
Common Equity, 1 Yr. Growth % | 33.86 | -23.07 | -14.06 | 36.48 | -21.04 | |||||
Cash From Operations, 1 Yr. Growth % | 250.55 | -33.62 | 9.24 | -9.72 | 21.65 | |||||
Capital Expenditures, 1 Yr. Growth % | -87.35 | 2.56T | 526.52 | -96.86 | 48.44 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -7.32T | -29.33 | 2.39 | -15.12 | 44.02 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -7.15T | -29.32 | 2.42 | -15.17 | 44.04 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -68.23 | 10.93 | 81.06 | 21.23 | -20.66 | |||||
Gross Profit, 2 Yr. CAGR % | -73.74 | 5.2 | 104.81 | 10.29 | -27.38 | |||||
EBITDA, 2 Yr. CAGR % | 85.44 | -3.92 | -5.98 | 10.59 | -3.97 | |||||
EBITA, 2 Yr. CAGR % | 80.88 | -4.29 | -5.77 | 11.06 | -3.67 | |||||
EBIT, 2 Yr. CAGR % | 69.39 | -5.36 | -6.55 | 8.04 | -5.79 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -36.9 | 25.06 | 61.53 | -6.95 | 17.67 | |||||
Net Income, 2 Yr. CAGR % | -36.9 | 23.84 | 57.51 | -7.33 | 19.61 | |||||
Normalized Net Income, 2 Yr. CAGR % | 25.52 | -11.58 | -11.1 | 7.79 | -6.48 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -44.32 | 6.88 | 51.92 | -7.67 | 18.09 | |||||
Accounts Receivable, 2 Yr. CAGR % | -81.69 | 0.58 | 11.29 | 21.41 | 3.69 | |||||
Inventory, 2 Yr. CAGR % | 85.28 | 84.94 | 12.31 | -5.15 | -2.5 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -11.88 | -37.31 | 45.5 | 60.25 | -27.57 | |||||
Total Assets, 2 Yr. CAGR % | 33.17 | 2.8 | -16.02 | 6.35 | -0.18 | |||||
Tangible Book Value, 2 Yr. CAGR % | 56.32 | 6.56 | -17.86 | 9.2 | 3.82 | |||||
Common Equity, 2 Yr. CAGR % | 42.33 | 1.48 | -18.69 | 8.3 | 3.81 | |||||
Cash From Operations, 2 Yr. CAGR % | 9.2 | 52.55 | -14.84 | -0.69 | 4.8 | |||||
Capital Expenditures, 2 Yr. CAGR % | - | 83.31 | 1.19T | -55.62 | -78.4 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 27.71 | 614.39 | -14.94 | -6.78 | 10.56 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 27.73 | 606.07 | -14.92 | -6.79 | 10.54 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -34.08 | -46.3 | 38.01 | 31.14 | 10.38 | |||||
Gross Profit, 3 Yr. CAGR % | -40.01 | -53.35 | 46.63 | 21.45 | 14.53 | |||||
EBITDA, 3 Yr. CAGR % | 47.22 | 34.96 | 4.51 | -4.38 | 4.47 | |||||
EBITA, 3 Yr. CAGR % | 44.87 | 32.77 | 4.38 | -4.09 | 4.83 | |||||
EBIT, 3 Yr. CAGR % | 46.06 | 26.83 | 3.23 | -6.02 | 2.92 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 23.95 | 27.93 | -8.1 | 65.74 | -11.76 | |||||
Net Income, 3 Yr. CAGR % | 23.95 | 27.1 | -9.63 | 64.2 | -11.7 | |||||
Normalized Net Income, 3 Yr. CAGR % | 50.61 | -0.12 | -0.77 | -9.76 | 3.01 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 7.69 | 14.08 | -18.04 | 59.82 | -12.4 | |||||
Accounts Receivable, 3 Yr. CAGR % | -34.22 | -63.55 | -4.63 | 28.64 | -2.68 | |||||
Inventory, 3 Yr. CAGR % | 901.56 | 65.45 | 48.43 | 5.88 | -3.13 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -39.48 | -22.94 | 12.18 | 14.82 | 23.51 | |||||
Total Assets, 3 Yr. CAGR % | 18.98 | 12.5 | -2.45 | -3.16 | -4.35 | |||||
Tangible Book Value, 3 Yr. CAGR % | 28.03 | 23.59 | -0.27 | -2.7 | -1.99 | |||||
Common Equity, 3 Yr. CAGR % | 18.5 | 15.94 | -3.99 | -3.37 | -2.52 | |||||
Cash From Operations, 3 Yr. CAGR % | 76.8 | -7.49 | 36.48 | -13.17 | 6.26 | |||||
Capital Expenditures, 3 Yr. CAGR % | -74.36 | - | 176.12 | 73.61 | -33.63 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 44.69 | 4.85 | 273.86 | -15 | 7.77 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 44.67 | 4.86 | 270.99 | -15 | 7.77 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 6.85 | -5.45 | -1.25 | -25.62 | 10.6 | |||||
Gross Profit, 5 Yr. CAGR % | -0.27 | -10.28 | -1.97 | -34.18 | 10.7 | |||||
EBITDA, 5 Yr. CAGR % | 9.1 | 13.55 | 23.04 | 24.62 | 1.03 | |||||
EBITA, 5 Yr. CAGR % | 8.64 | 12.69 | 21.97 | 23.62 | 1.08 | |||||
EBIT, 5 Yr. CAGR % | 9.98 | 9.36 | 22.17 | 18.95 | -0.48 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -16.02 | 18.84 | 37.8 | 12.64 | 1.45 | |||||
Net Income, 5 Yr. CAGR % | -16.02 | 18.37 | 36.42 | 12.01 | 1.09 | |||||
Normalized Net Income, 5 Yr. CAGR % | 13.33 | 4.98 | 21.97 | 2.97 | -3.1 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -24.76 | 6.37 | 23.58 | 4.82 | -5.15 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | 87.75 | -18.82 | -41.02 | -1.39 | |||||
Inventory, 5 Yr. CAGR % | - | - | 317.42 | 32.44 | 25.46 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -7.96 | -12.08 | -14.05 | 3.28 | -5.83 | |||||
Total Assets, 5 Yr. CAGR % | 20.66 | 18.45 | 3.5 | 10 | -1.55 | |||||
Tangible Book Value, 5 Yr. CAGR % | 19.96 | 18.32 | 7.21 | 17.62 | 1.35 | |||||
Common Equity, 5 Yr. CAGR % | 19.42 | 18.7 | 1.93 | 12.82 | -0.94 | |||||
Cash From Operations, 5 Yr. CAGR % | 25.83 | 34.44 | 32 | -4.83 | 22.8 | |||||
Capital Expenditures, 5 Yr. CAGR % | -52.1 | 1.85 | 22.92 | - | -0.36 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 28.07 | 107.12 | 17 | 0.03 | 129.65 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 28.06 | 107.1 | 16.99 | 0.04 | 128.57 |
- Stock Market
- Stocks
- 6535 Stock
- Financials Lumosa Therapeutics Co., Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















